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RECENT TRENDS IN INPATIENT DRUG COSTS: 2000–2002
Foster DA
Solucient, LLC, Ann Arbor, MI, USA
OBJECTIVES: To evaluate the extent to which case-mix-
adjusted, hospital inpatient costs for pharmaceutical services
changed from 2000 through 2002 in short-term, general, non-
federal (STGNF) hospitals in the U.S., and to identify hospital
characteristics that were signiﬁcantly associated with such
changes. METHODS: Using all-payer data from more than 2500
STGNF hospitals, discharge-level drug costs were estimated
using the Medicare Cost Report information on revenue-center-
speciﬁc cost-to-charge ratios applied to the corresponding hos-
pital charges. Cost estimates were analyzed by all DRGs to
identify those in which statistically signiﬁcant (alpha = 0.05)
upward or downward trends were detected. Pharmacy costs 
relative to other hospital costs were also analyzed, as was the
variability across hospitals in case-mix-adjusted average phar-
maceutical cost. Hospital characteristics were evaluated as pre-
dictors of case-mix-adjusted average pharmaceutical costs, and
national estimates of total hospital pharmaceutical costs were
estimated for selected DRG-deﬁned clinical groups. RESULTS:
Numerous DRGs exhibited signiﬁcant upward or downward
trends in average costs per case for pharmaceutical services from
2000 through 2002. Signiﬁcant trends over time in the propor-
tion of total hospital costs that were attributable to pharmaceu-
tical services were also detected. Extensive variability across
hospitals was detected in both the total costs that were due to
pharmaceutical services, as well as the proportion of the total
costs that were due to pharmaceutical services. Many DRGs
exhibited substantial increases in the average dollar amount of
costs for drug treatment from 2000 through 2002. CON-
CLUSIONS: Inpatient costs for pharmaceutical services have
increased substantially in recent years relative to other hospital
services areas, such as laboratory and diagnostic radiology.
Further, there exists extensive variability in the intensity of phar-
maceutical services that are provided, even after case-mix adjust-
ment. Finally, numerous hospital characteristics, such as teaching
status and size, are signiﬁcantly correlated with the relative 
utilization of pharmaceutical services for the treatment of 
inpatients.
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OBJECTIVE: To investigate the occurrence of all drug-related
problems (DRPs) amongst hospitalised patients on polyphar-
macy, and to conﬁrm the association of advanced age and the
female gender with adverse drug reactions (ADRs). METHODS:
A retrospective, cross-sectional study was carried out in patients
on polypharmacy (5 and more drugs). Chi-square test was used
to test for signiﬁcant differences (p < 0.05) between the age and
gender of patients, and their risk of developing DRPs. A two-
tailed, unpaired t-test was employed to test for signiﬁcant dif-
ference (p < 0.05) between the number of medications taken and
the risk of DRPs. Relative risk (RR) analysis was performed for
geriatric (patients above 65 years old) and female patients to
assess their propensity in developing ADRs. RESULTS: The
study population consisted of 347 patients (43% female), aged
16–97 (average 66 years). Geriatrics made up 58.2% of this pop-
ulation. The number of medications per patient ranged from 5
to 14 (mean 7.4 ± 2.1). The types of DRPs identiﬁed included:
inappropriate treatment (42.9%); potential drug interactions
(45.0%); inappropriate dosages (20.7%); unsafe drugs for
patients (13.5%); ADRs (7.5%). There were no statistical cor-
relations when age and gender were compared between patients
with and without DRPs. However, number of medications taken
was a risk factor for the presence of DRPs (p = 0.001). RR for
geriatrics and female patients to develop ADRs are found to be
1.01 (95% CI: 0.52, 1.85) and 0.79 (95% CI: 0.40, 1.55),
respectively. CONCLUSION: Our results established that DRPs
in hospitalised patients on polypharmacy in Singapore is com-
parable to that in other developed countries. Our results also
support that polypharmacy is a greater risk factor than age
where high susceptibility for DRPs, especially ADRs is con-
cerned. The low RR of geriatrics and female patients developing
ADRs deviates from published results and may be confounded
by our inclusion criteria.
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COMPARING THE COSTS OF MAIL ORDER AND 
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Carroll NV1, Brusilovsky I2,York B2, Oscar R2
1Virginia Commonwealth University, Richmond,VA, USA; 2Rx-EOB,
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OBJECTIVE: To compare the costs of prescriptions dispensed
through mail order and retail pharmacies. We examined total
costs, costs to health plan sponsors, and costs to health plan
members. METHODS: We compared the actual cost of pre-
scriptions dispensed through a mail order pharmacy with what
those same prescriptions would have cost if dispensed through
retail pharmacies. We based our analysis on prescription claims
submitted to a health plan in the northeastern United States
between July 1, 2002 and June 30, 2003. The plan covered about
100,000 members. The plan used a mail-order pharmacy that
was not owned by a major PBM, a 3-tier beneﬁt design, and
speciﬁed that patients’ could get a 90-day supply through mail
order for the equivalent of two 30-day retail copays. Retail phar-
macies were paid a $2.00 dispensing fee per 30-day supply dis-
pensed. The mail-order pharmacy charged no dispensing fee. 
For brand name drugs, the plan paid AWP less 15% to retail
pharmacies and AWP less 17% to the mail-order pharmacy.
RESULTS: Total costs for the 44,847 prescriptions dispensed
through mail order were $6,401,624. Had these prescriptions
been dispensed at retail, costs would have been $6,902,252.
Ingredient costs were $6,401,624 through mail versus
$6,633,170 at retail. Total costs to the health plan were
$4,726,637 through mail versus $4,417,733 at retail. Member
costs were $1,674,987 through mail versus $2,484,519 at retail.
CONCLUSIONS: Mail order was less expensive overall, but
more expensive to the health plan. The loss of copays in the mail
order plan was greater than the savings on ingredient costs and
dispensing fees.
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